MedTrace Logo

High Dose Bupropion for Smoking Cessation - Pilot Study

NCT03326128 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2023-07-17

No results posted yet for this study

Summary

This study aims to investigate the benefit of administering two differing doses of Bupropion (BUP) to smokers to assist with smoking cessation.

Conditions

  • Smoking Cessation
  • Smoking, Tobacco
  • Smoking (Tobacco) Addiction
  • Cessation, Tobacco
  • Cigarette Smoking

Interventions

DRUG

Bupropion Hydrochloride

Antidepressant that is also effective in smoking cessation

Sponsors & Collaborators

Principal Investigators

  • Adam M Leventhal, PhD · University of Southern California

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-09-01
Primary Completion
2023-07-01
Completion
2023-07-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03326128 on ClinicalTrials.gov